This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feng, T.
Right arrow Articles by Zhang, D. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feng, T.
Right arrow Articles by Zhang, D. Y.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2008, p. 2463-2465, Vol. 46, No. 7
0095-1137/08/$08.00+0     doi:10.1128/JCM.02363-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Effect of Epstein-Barr Virus Sequence Variation on Performance of the Roche Real-Time LightCycler PCR Assay {triangledown}


arrow
LETTER
 
Epstein-Barr virus (EBV), one of the most common human viruses, is a member of the Herpesviridae family. EBV infects more than 90% of the world's population and remains latent in B-cell lymphocytes. EBV is associated with the development of certain malignancies, including lymphoma and posttransplant lymphoproliferative disease (PTLD). The monitoring of EBV viral load in peripheral blood is important for guiding empirical treatment of transplant recipients to prevent the development of PTLD. Recently, Roche Diagnostics developed an analyte-specific reagent for real-time LightCycler PCR to detect EBV. The assay amplifies the EBV latent membrane protein 2a gene (LMP2a) by utilizing a pair of PCR primers and a set of hybridization probes labeled with LightCycler Red 640 and fluorescein for amplicon detection.

From 1 November 2005 through 31 July 2007, a total of 644 patients were tested in our laboratory. Multiple samples were received from the same patient for monitoring purposes. In addition, 197 of the 644 patients were EBV positive at some point during the study (limit of detection = 12 EBV copies/reaction). Samples received from six patients and one external exchange specimen exhibited 7°C peak shifts in melting curve (55°C versus the expected 62°C) (Table 1 and Fig. 1A and B). To determine the cause of the shifted melting temperature (Tm), additional PCRs using primers specific to the EBV LMP2a gene (nucleotides 166704 to 166985) were performed. Electrophoresis of PCR products from samples with the expected (62°C) and shifted (55°C) melting curves revealed the same band size (Fig. 1C). Further, sequencing of PCR products by use of a fluorescence chain terminator method revealed a common variation (G->T) at the 166905 position of the EBV genome (EBV strain B95-8; GenBank accession no. V01555) compared to the DNAs without Tm shifts (Table 1). To confirm this sequence variation, a Tm analysis was performed by adding fluorescent probes (primer/hybridization probes; Roche LightCycler EBV assay) to the purified PCR DNA in the presence of reaction buffer (Roche LightCycler FastStart DNA Master HybProbe, vial 1b). The results confirmed that the G->T nucleotide change at position 166905 caused a 7°C shift of the melting curve (Fig. 1D).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Sequencing analysis of 13 EBV-positive samplesa


Figure 1
View larger version (25K):
[in this window]
[in a new window]

  		FIG. 1. Melting curve analysis of EBV PCR products. (A and B) The amplification curve of a sample (sample B) with a shifted melting curve is compared with that of the EBV standard (STD). Although the threshold cycle (CP) value (28.87), copy number (343.8), and sigmoid amplification curve are consistent with a positive result for sample B (A), the melting curve analysis revealed a 7°C left shift for sample B compared to the level for the standard (channel F2/back F1) (B). (C) PCR primers specific for LMP2 were used on specimens with and without shifted melting curves (samples 2, 7C, 8B, and 8C in Table 1). Gel electrophoresis of the PCR products demonstrated the same band size. (D) After purification of PCR products, the fluorescent probe (primer/hybridization probes; Roche LightCycler EBV assay) as well as buffer (Roche LightCycler FastStart DNA Master HybProbe, vial 1b) was added to the PCR products and the melting curve analysis was performed using programs 1, 3, and 4 (95°C for 10 min, 40°C for 60 s, and 40°C for 30 s) on the LightCycler. The results showed that the samples with shifted melting curves had Tms of 55°C, but the samples without shifted curves had Tms of 62°C. These results confirmed that the sequence variation (G->T) at position 166905 was caused by a shifted melting curve. n/a, not applicable; N, negative EBV patient sample; W, water blank control.

Within the 282-nucleotide fragment, we identified five additional sequence variations at different locations (Table 1). It is interesting to note that the five additional sequence variations occurred only in samples without shift of the Tm. Some variations altered the amino acid sequence, while others did not (Table 1). However, these changes may not alter the viral replication or virulence (1). Based on the presented data, the specific sequence variation observed in a particular patient remains stable over time. For example, three samples, obtained on 27 December 2005, 8 March 2006, and 17 May 2006, demonstrated the same G->T change at position 16905. This finding is consistent with a previous report indicating that in chronically EBV-infected patients, the dominant EBV strains remained unchanged over several years (3).

EBV sequence variation is a recognized phenomenon (2-4) and has been used for EBV genotyping (4). Sequencing of the carboxyl-terminal region of the LMP1 gene showed that multiple variants (one to seven clones) may coexist in an individual (3). In addition, active EBV infection may be caused by endogenous EBV reactivation in posttransplant recipients (2).

It is important for a clinical laboratory performing EBV viral load testing to recognize the G->T nucleotide change at position 166905. The incidence of this particular variant represented 3% of our patient population (7 of 197 patients). Therefore, encountering this phenomenon is not a rare diagnostic circumstance. Although the precise fluorescent probe binding site is proprietary information, it has become evident that the unique EBV sequence variation interferes with one of the fluorescent hybridization probes during EBV target binding, resulting in a shifted melting curve. Therefore, carefully analyzing PCR amplification and melting curves is paramount for avoiding false-negative and false-positive data interpretation. Furthermore, samples with shifted melting curves of 62°C ± 2°C should not be hastily considered negative. Reflex testing for sequencing analysis should be performed to identify EBV sequence variants and exclude nonspecific amplification or background fluorescence.


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 14 May 2008. Back


arrow
REFERENCES
 
    1
  1. Mainou, B. A., and N. Raab-Traub. 2006. LMP1 strain variants: biological and molecular properties. J. Virol. 80:6458-6468.[Abstract/Free Full Text]
    2. 2
  2. Meijer, E., S. Spijkers, S. Moschatsis, G. J. Boland, S. F. T. Thijsen, A. M. van Loon, and L. F. Verdonck. 2005. Active Epstein-Barr virus infection after allogenic stem cell transplantation: re-infection or reactivation? Transpl. Infect. Dis. 7:4-10.[CrossRef][Medline]
    3. 3
  3. Shibata, Y., Y. Hoshino, S. Hara, H. Yagasaki, S. Kojima, Y. Nishiyama, T. Morishima, and H. Kimura. 2006. Clonality analysis by sequence variation of the latent membrane protein 1 gene in patients with chronic active Epstein-Barr virus infections. J. Med. Virol. 78:770-779.[CrossRef][Medline]
    4. 4
  4. Walling, D. M., L. A. Andritsos, W. Etienne, D. A. Payne, J. F. Aronson, C. M. Flaitz, and C. M. Nichols. 2004. Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative disease. J. Med. Virol. 74:94-101.[CrossRef][Medline]
Tao Feng
Fei Ye
Josephine Wu
Shiquan Jiang
Jennifer Coolbaugh
Department of Pathology

Benjamin Shneider
Betsy Herold
Department of Pediatrics

Sukru Emre
Department of Surgery

David Y. Zhang*
Department of Pathology
Mount Sinai School of Medicine
One Gustave L. Levy Place
Box 1122
New York, New York 10029

* Phone: (212) 659-8173
Fax: (212) 427-2082
E-mail: david.zhang{at}mssm.edu

Journal of Clinical Microbiology, July 2008, p. 2463-2465, Vol. 46, No. 7
0095-1137/08/$08.00+0     doi:10.1128/JCM.02363-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feng, T.
Right arrow Articles by Zhang, D. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feng, T.
Right arrow Articles by Zhang, D. Y.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»